• 1
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005; 55: 74108.
  • 2
    El Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 74550.
  • 3
    Sangiovanni A, Del Ninno E, Fasani P, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004; 126: 100514.
  • 4
    Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. The Lancet 2003; 362: 190717.
  • 5
    Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 120836.
  • 6
    Bruix J, Sherman M, Llovet JM, et al. Clinical management on hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001; 35: 421430.
  • 7
    Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 42942.
  • 8
    Jadad A, Moore A, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials 1996; 17: 112.
  • 9
    National Cancer Institute. National Cancer Institute website. US National Institute of Health. Last accessed February 15 2006.
  • 10
    Poon RT, Fan ST, Tsang FH, Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 2002; 235: 46686.
  • 11
    Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology 2000; 32: 12249.
  • 12
    Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30: 143440.
  • 13
    Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 6939.
  • 14
    Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005; 25: 181200.
  • 15
    Schwartz JD, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 2002; 3: 593603.
  • 16
    Sala M, Llovet JM, Vilana R, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004; 40: 135260.
  • 17
    Lencioni R, Cioni D, Crocetti L, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 2005; 234: 9617.
  • 18
    Omata M, Tateishi R, Yoshida H, Shiina S. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation. Gastroenterology 2004; 127: S15966.
  • 19
    Huang GT, Lee PH, Tsang YM, et al. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann Surg 2005; 242: 3642.
  • 20
    Lin SM, Lin CJ, Lin CC, et al. Randomized controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005; 54: 11516.
  • 21
    Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology. 2005; 129: 12230.
  • 22
    Lin SM, Lin CJ, Lin CC, et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma <or = 4 cm. Gastroenterology 2004; 127: 171423.
  • 23
    Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228: 23540.
  • 24
    Shibata T, Iimuro Y, Yamamoto Y, et al. Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology 2002; 223: 3317.
  • 25
    Lin JJ, Jin CN, Zheng ML, et al. Clinical study on treatment of primary hepatocellular carcinoma by Shenqi mixture combined with microwave coagulation. Chin J Integr Med 2005; 11: 10410.
  • 26
    Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004; 127: S17988.
  • 27
    Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 17349.
  • 28
    Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 116471.
  • 29
    Group d'Etude et de Traitment du Carcinome Hépatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 125661.
  • 30
    Raoul JL, Guyader D, Bretagne JF, et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997; 26: 115661.
  • 31
    Homma H, Mezawa S, Doi T, et al. A comparative randomized trial of intermittent intrahepatic arterial carboplatin- versus doxorubicin-lipiodol emulsion in advanced hepatocellular carcinoma (stage IV). Hepatogastroenterology 2004; 51: 11359.
  • 32
    Akamatsu M, Yoshida H, Obi S, et al. Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial. Liver Int 2004; 24: 6259.
  • 33
    Becker G, Soezgen T, Olschewski M, et al. Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World J Gastroenterol 2005; 11: 61049.
  • 34
    Fong Y, Kemeny N, Lawrence T. Cancer of the liver and biliary tree. In: De VitaVT, HellmanS, RosenbergS, eds. Cancer: Principles and Practices of Oncology. Philadelphia, USA: Lippincott Williams and Wilkins, 2001: 1162204.
  • 35
    Palmer D, Hussain S, Johnson P. Systemic therapies for hepatocellular carcinoma. Expert Opin Investig Drugs 2004; 13: 155568.
  • 36
    Barbare JC, Bouche O, Bonnetain F, et al. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol 2005; 23: 433846.
  • 37
    Chow PK, Tai BC, Tan CK, et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology 2002; 36: 12216.
  • 38
    Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen. Hepatology 2004; 40: 13619.
  • 39
    Pan DY, Qiao JG, Chen JW, et al. Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial. Hepatobiliary Pancreat Dis Int 2003; 2: 2115.
  • 40
    Yuen MF, Poon RT, Lai CL, et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002; 36: 68791.
  • 41
    Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97: 15328.
  • 42
    Beaugrand M, Sala M, Degos F, et al. Treatment of advanced hepatocellular carcinoma by seocalcitol (a vit D analogue): an International randomized double-blind placebo-controlled study in 747 patients. J Hepatol 2000; 42: 17A.
  • 43
    Porta C, Ruff R, Feld L, et al. Results of a Phase III Randomized Controlled Study, the Largest Ever Completed in Hepatocellular Carcinoma (HCC), Comparing the Survival of Patients with Unresectable HCC Treated with Nolatrexed (NOL) or Doxorubicin (DOX). ASCO 2006 Gastrointestinal Symposium Proceedings. Lippincott Williams & Wilkins: Baltimore, 2006: p. 133A.
  • 44
    Posey J, Johnson P, Mok T, et al. Results of a phase 2/3 open-label, randomized trial of T138067 versus doxorubicin in chemotherapy-naive, unresectable hepatocellular carcinoma. J Clin Oncol 2005; 23: 16S, 316S.